Osteologix to Continue Development of Osteoporosis Drug
Osteologix is positioning NB S101 as an alternative to traditional osteoporosis treatments.
feature2
Positive Rheumatoid Arthritis Data for UCB, Trubion, Others
Data presented this weekend at the American College of Rheumatology’s annual meeting indicated that rheumatoid arthritis patients who adhered to a prescription drug regimen had better medical outcomes and lower medical costs.
Onyx Pharmaceuticals to Acquire Proteolix
Onyx Pharmaceuticals has agreed to purchase private biotechnology company Proteolix for $276 million in cash.
Positive Phase II Data for Peregrine’s Lung Cancer Treatment
Peregrine Pharmaceuticals reported positive Phase II data in a clinical trial of bavituximab in patients with a deadly form of lung cancer.
Biotech News Out of Quebec
Medicago, a Canadian company focused on protein-based vaccines, has signed a contract with the U.S. Army to investigate ways to create biofuels from plants.
Two Pharma Companies to Offer Discounted Shares
Repros and Targacept have announced plans to offer shares in their respective companies at a reduced cost.
Acadia and Biovail Not Giving Up on Parkinson’s Drug
Acadia and its partner Biovail made news last month with a failed late-stage trial of pimavanserin, their experimental drug candidate to treat psychosis related to Parkinson’s disease.
Three Companies Race for Obesity Drug Approval
The race for an anti-obesity drug intensified Wednesday with the latest mid-stage trial data from Orexigen Therapeutics.
BioSante (NASDAQ: BPAX): LibiGel Provides Big Upside Potential
On 9/22/09, BioSante and Cell Genesys (NASDAQ: CEGE) announced that they have determined the final exchange ratio will be 0.1828 in connection with the previously announced merger between the companies.
FDA Approves Centocor’s Psoriasis Treatment
After a long delay, Centocor Ortho Biotech’s psoriasis drug Stelara has been approved by the U.S. Food and Drug Administration.